Ma, Rui
Liaoning Cancer Hospital & Institute
3 papers on CoChatORCID 0000-0001-9317-9377
Most cited papers
- Verified
Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11)
Yang, Y., Wang, Z., Fang, J., Yu, Q., Han, B., Cang, S., Chen, G., Mei, X., Yang, Z., Ma, R., et al. (2020) · Journal of Thoracic Oncology
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 390
- Verified
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
Zhou, C., Wang, Z., Sun, M., Cao, L., Ma, Z., Wu, R., Yu, Y., Yao, W., Sun, S., Chen, J., et al. (2025) · The Lancet Oncology
Lung Cancer Treatments and MutationsCancer Immunotherapy and Biomarkers
Cited by 23
- Verified
Datopotamab deruxtecan (Dato-DXd) in Chinese patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC): Results from the phase 1/2 TROPION-PanTumor02 study.
Sun, Y., Xiao, Z., Cheng, Y., Li, J., Tu, H. Y., Long, J., Lin, X., Li, W., Zhao, J., Wang, Y., et al. (2024) · Journal of Clinical Oncology
Lung Cancer Treatments and MutationsLung Cancer Research Studies
Cited by 9
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free